search
Back to results

An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery

Primary Purpose

Kidney Failure, Acute, Kidney Failure, Chronic, Cardiac Surgical Procedures

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
N-acetylcysteine
fenoldopam
Sponsored by
Linda F. Barr, M.D.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Kidney Failure, Acute focused on measuring Kidney failure, Cardiac Surgery, Fenoldopam, N-acetylcysteine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Chronic creatinine clearance </= 40cc/h Pre-operative cardiac surgery Exclusion Criteria: Pre-operative ongoing dialysis Nausea and vomiting Uncontrolled glaucoma Allergy to metabisulfite Enrollment in another clinical study within 30 days Pregnancy Acute renal failure

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    NAC

    fenoldopam

    NAC and fenoldopam

    Control

    Arm Description

    N-acetylcysteine started day prior to surgery, continued through night of surgery

    fenoldopam started at surgery continued for 24 hours

    Both N-acetylcysteine and fenoldopam as above

    Placebo

    Outcomes

    Primary Outcome Measures

    Length of post-operative hospital stay
    Length of post-operative critical care stay
    Creatinine clearance post-operative days 3, 14, and nadir

    Secondary Outcome Measures

    Days to post-operative creatinine clearance nadir
    Intraoperative and post-operative pressor use (pressor-hours)
    Hospital costs
    Mortality

    Full Information

    First Posted
    July 14, 2005
    Last Updated
    November 6, 2014
    Sponsor
    Linda F. Barr, M.D.
    Collaborators
    Abbott
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00122018
    Brief Title
    An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
    Official Title
    N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2002 (undefined)
    Primary Completion Date
    March 2006 (Actual)
    Study Completion Date
    March 2006 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Linda F. Barr, M.D.
    Collaborators
    Abbott

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Patients with abnormal kidney function are at increased risk for complications following heart surgery, including worsening kidney function possibly requiring dialysis, a prolonged stay in the critical care unit and hospital, and the increased risk of death. Prior attempts at kidney protection for heart surgery patients have had mixed results. Two medicines, fenoldopam and N-acetylcysteine, have been shown to protect kidney function in other circumstances that cause kidney stress. The purpose of this study is to determine whether these medications will help to maintain the function of diseased kidneys during heart surgery.
    Detailed Description
    This is a randomized, double-blinded, placebo-controlled trial to evaluate fenoldopam and N-acetylcysteine (NAC) individually, and together, as renal protective agents for patients with renal insufficiency undergoing heart surgery. Subjects have chronic renal insufficiency with creatinine clearance (CrCl) </= 40cc/min but not on pre-operative dialysis, and receive: NAC 600 mg by mouth (po) twice a day (bid) or placebo starting 24 hours pre-operative and continuing through the day of surgery; and/or fenoldopam 0.1 mcg/kg/min intravenous (IV) or saline placebo at anesthetic induction and continuing for 48 hours. Outcome data include: nadir, post-operative day 3 and post-operative day 14 CrCl, time to CrCl nadir, length of Intensive Care Unit (ICU) stay, length of post-operative hospital stay, hospital costs, mortality, and the need for hemodialysis. Intraoperative and post-operative pressor use is being monitored. The enrollment will include 80 patients (20 in each group).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Kidney Failure, Acute, Kidney Failure, Chronic, Cardiac Surgical Procedures
    Keywords
    Kidney failure, Cardiac Surgery, Fenoldopam, N-acetylcysteine

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 2
    Interventional Study Model
    Factorial Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    80 (false)

    8. Arms, Groups, and Interventions

    Arm Title
    NAC
    Arm Type
    Experimental
    Arm Description
    N-acetylcysteine started day prior to surgery, continued through night of surgery
    Arm Title
    fenoldopam
    Arm Type
    Experimental
    Arm Description
    fenoldopam started at surgery continued for 24 hours
    Arm Title
    NAC and fenoldopam
    Arm Type
    Experimental
    Arm Description
    Both N-acetylcysteine and fenoldopam as above
    Arm Title
    Control
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo
    Intervention Type
    Drug
    Intervention Name(s)
    N-acetylcysteine
    Other Intervention Name(s)
    Mucomyst
    Intervention Type
    Drug
    Intervention Name(s)
    fenoldopam
    Other Intervention Name(s)
    Corlopam
    Primary Outcome Measure Information:
    Title
    Length of post-operative hospital stay
    Time Frame
    30-day
    Title
    Length of post-operative critical care stay
    Time Frame
    30-day
    Title
    Creatinine clearance post-operative days 3, 14, and nadir
    Time Frame
    14 day
    Secondary Outcome Measure Information:
    Title
    Days to post-operative creatinine clearance nadir
    Time Frame
    14 day
    Title
    Intraoperative and post-operative pressor use (pressor-hours)
    Time Frame
    48 hour
    Title
    Hospital costs
    Time Frame
    30-day
    Title
    Mortality
    Time Frame
    30-day

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Chronic creatinine clearance </= 40cc/h Pre-operative cardiac surgery Exclusion Criteria: Pre-operative ongoing dialysis Nausea and vomiting Uncontrolled glaucoma Allergy to metabisulfite Enrollment in another clinical study within 30 days Pregnancy Acute renal failure
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Linda F Barr, MD
    Organizational Affiliation
    Pulmonary and Critical Care Assoc. of Baltimore
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    18434903
    Citation
    Barr LF, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med. 2008 May;36(5):1427-35. doi: 10.1097/CCM.0b013e31816f48ba.
    Results Reference
    result

    Learn more about this trial

    An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery

    We'll reach out to this number within 24 hrs